AOD 9604 peptide vs retatrutide: what the evidence shows

Last updated 2026-07-25

What is AOD 9604 and how does it compare to retatrutide mechanistically?

AOD 9604 is a synthetic fragment of human growth hormone, specifically the C-terminal region (amino acids 176-191) that researchers isolated because it seemed responsible for HGH's fat-metabolizing effects without the growth-promoting ones. The idea, dating back to research programs in the early 2000s, was to get lipolysis without the risks of full-length growth hormone. It's been sold for years in gray-market research chemical circles as a fat-loss peptide. Retatrutide works completely differently. It's a triple agonist that hits three separate receptors at once: GIP, GLP-1, and glucagon ^[1]. That's a broader mechanism than semaglutide, which only hits the GLP-1 receptor, or tirzepatide, which hits GIP and GLP-1 but not glucagon ^[1]. The glucagon receptor activity is what researchers think gives retatrutide its edge on energy expenditure, on top of the appetite suppression you get from GLP-1 and GIP agonism. So you're not really comparing two versions of the same drug class. AOD 9604 is a growth-hormone-derived fragment peptide with a proposed lipolytic action. Retatrutide is an incretin/glucagon receptor agonist in the same broad family as semaglutide and tirzepatide, just with one more receptor added. The mechanisms don't overlap, and the strength of the human evidence behind them isn't close either.

What does the clinical evidence actually show for each?

This is where the comparison gets lopsided. Retatrutide has a published, peer-reviewed phase 2 obesity trial in the New England Journal of Medicine. At the 12 mg weekly dose, participants lost a mean of 24.2% of body weight at 48 weeks, compared to 2.1% for placebo ^[1]. The trial is registered on ClinicalTrials.gov as NCT04881760, listing LY3437943 (retatrutide's development code), the dose arms tested, and the weekly subcutaneous injection route ^[2]. It's also moved into later-phase registered trials, with public records for at least two more studies (NCT05929066 and NCT05882045) laying out enrollment criteria, comparators, and endpoints ^{[3] [4]}. There's also a separate registered type 2 diabetes program, so the evidence base isn't limited to weight loss alone ^[2]. AOD 9604 doesn't have anything close to that depth of evidence in humans. It went through some early-stage obesity trials years ago, and the results were unimpressive enough that development largely stalled out; it never generated the kind of large, randomized, peer-reviewed weight-loss data that retatrutide has. If you search for it today, you mostly find gray-market vendor claims and small or preclinical studies, not the kind of dosed, placebo-controlled trial data that changes clinical practice. The honest comparison: retatrutide has trial-grade human evidence showing a specific, quantified effect. AOD 9604 has a plausible-sounding mechanism and old, thin data that never supported a real drug development program to approval. That gap matters a lot if you're trying to decide whether either substance is worth researching further, let alone anything else.

Is AOD 9604 FDA-approved? Is retatrutide?

Neither is approved for any indication in the United States. A query of Drugs@FDA, the FDA's own database of approved drug products, returns no approved product for the generic name retatrutide ^[1]. AOD 9604 has never had an approved new drug application either; it's never made it through phase 3 trials to an approval decision in the US. That means both substances are, legally, unapproved new drugs. Under 21 U.S.C. 355, a new drug can't be introduced into interstate commerce without an approved application ^[5]. That's the statutory reason neither one is available at a pharmacy, from a doctor's prescription pad, or through any legitimate US supply chain right now.

Can either one be legally compounded by a US pharmacy?

No, and the reasoning is worth understanding because it applies to almost every 'research peptide' you'll see marketed alongside retatrutide. Section 503A compounding requires a strict cascade: the substance must comply with a USP or NF monograph if one exists; if no monograph exists, it must be a component of an FDA-approved drug; only if neither of those applies can it come from the 503A Bulks List ^[6]. Retatrutide fails all three tests. It has no monograph, it's not a component of any approved drug, and it isn't on the Bulks List. The final 503A Bulks List contains exactly six substances (Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide) ^[7]. No peptide is on it, and retatrutide has never been nominated for it. FDA's public nominations list confirms this; retatrutide simply doesn't appear on the roster of substances under consideration ^{[8] [9]}. AOD 9604 is in the same position. It's not on the 503A list, and it hasn't gone through the kind of nomination and advisory review process that some other peptides have. In July 2026, FDA's Pharmacy Compounding Advisory Committee actually met to consider seven different peptides for the Bulks List: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), semax, and epitalon ^[10]. Neither retatrutide nor AOD 9604 was among them. And even for the peptides that were reviewed, a favorable committee vote doesn't create a compounding pathway by itself; advisory recommendations are non-binding, and actually adding something to the Bulks List requires full notice-and-comment rulemaking ^[10], which takes time and isn't guaranteed to happen. Separately, 503A also requires that any bulk substance come from an establishment registered under FD&C Act section 510, with a valid certificate of analysis ^[6]. Research-use-only material from an unregistered overseas supplier fails this requirement no matter what else is true about the substance. That single fact rules out basically every gray-market vendor selling either peptide today. The 503B pathway, which governs outsourcing facilities rather than compounding pharmacies, has its own separate bulks list at 21 CFR 216.24, and it doesn't include retatrutide or AOD 9604 either ^[11]. There's no lawful compounding door open for either substance right now, full stop.

Why do vendor sites say these peptides are 'for research use only'?

Because the disclaimer is meant to create legal cover, and it mostly doesn't work. FDA's own regulation on intended use, 21 CFR 201.128, says intended use is established by labeling claims, advertising, and oral or written statements by the seller, not by a disclaimer sitting at the bottom of a page ^[12]. FDA has acted on this directly. In a March 2026 warning letter to Gram Peptides, the agency wrote that despite a research-use disclaimer, evidence from the company's own website established that its products were intended to be drugs for human use, and the letter specifically named retatrutide as one of the products marketed on that site ^[13]. So if a vendor's marketing copy talks about fat loss, appetite suppression, or dosing 'protocols,' that language is what determines the product's legal status, not the disclaimer sitting next to it. This is the same logic that would apply to AOD 9604 sold with fat-burning claims: the words on the page make it a drug claim, whatever the fine print says.

AOD 9604 vs retatrutide: side-by-side comparison

Does more clinical evidence mean retatrutide is safer to try?

No, and this is a common mistake. Better trial data means we know more about retatrutide's effects, both good and bad, in a controlled setting with real dosing, real monitoring, and real informed consent. It doesn't mean the drug is safe to self-administer outside that setting. The phase 2 trial dosed retatrutide by weekly subcutaneous injection, with participants monitored by trial staff and clinical protocols ^{[1] [2]}. That's a completely different situation from someone injecting a vial from an unregistered supplier with no idea what's actually in it, no verified purity, and no clinician tracking side effects. A certificate of analysis and manufacturer registration under FD&C Act section 510 exist precisely to prevent that gap ^[6], and gray-market retatrutide almost never has either. AOD 9604's weaker evidence base cuts the other way: there's less known about its effects at all, good or bad, which is its own kind of risk. Neither situation is one where a stronger or weaker trial record should be read as a green light to self-administer.

What has to happen before either peptide could be prescribed legally?

For retatrutide, the path is a completed phase 3 program followed by an FDA-approved New Drug Application. That's the same road semaglutide and tirzepatide already traveled. Semaglutide is approved and marketed as Ozempic and Wegovy, and tirzepatide as Mounjaro and Zepbound, both with published safety data behind them ^[5]. Retatrutide isn't there yet; its later-phase trials are still active ^{[3] [4]}. For AOD 9604, there isn't an active, publicly visible phase 3 program pushing toward approval in the way there is for retatrutide. Without a completed late-stage trial program and an approved application, 21 U.S.C. 355 keeps it out of interstate commerce as an unapproved new drug ^[5], same as retatrutide. A separate route exists only through the 503A Bulks List, and neither substance is on it or moving toward it in any documented way ^{[7] [9]}. Unless and until one of those two doors (full approval, or a rulemaking that adds the substance to the Bulks List) opens, nobody, including a licensed physician, can lawfully prescribe or dispense either peptide outside of a registered clinical trial.

Is it legal to import AOD 9604 or retatrutide from overseas for personal use?

FDA has a published personal importation policy, and it's the relevant rule here ^[14]. It generally covers narrow circumstances, like a drug for a serious condition with no US-approved treatment available, used under a doctor's supervision, in limited quantity, and not promoted to US consumers. Routine ordering of an unapproved peptide from a gray-market website for weight loss or fat reduction doesn't fit that narrow exception. Combined with the fact that these products still count as unapproved new drugs under 21 U.S.C. 355 ^[5], personal importation doesn't provide a legal workaround. It's a policy describing a narrow FDA enforcement discretion, not a green light for importing whatever you can find online.

What are the actual lawful options right now?

If you're dealing with obesity or excess weight and want something that's actually legal and clinician-supervised, there are FDA-approved options that didn't exist a few years ago. Semaglutide is approved as Ozempic and Wegovy, and tirzepatide as Mounjaro and Zepbound ^[5]. More recently, orforglipron, an oral GLP-1 receptor agonist, was approved as Foundayo under NDA 220934, in six strengths from 0.8 mg to 17.2 mg ^[5]. That gives patients a legal oral incretin option who might otherwise have gone looking for investigational compounds like retatrutide. NIDDK, the federal government's diabetes and digestive disease research body, also publishes neutral, evidence-based guidance on weight management that's worth reading regardless of what medication route you're considering . None of these approved options are AOD 9604 or retatrutide, but they're the closest things available today with real safety monitoring behind them, prescribed by a clinician who can adjust dose and watch for adverse effects in real time. If you want to understand what's known about retatrutide specifically, including its trial-reported side effect profile and the dosing schedules studied so far, see our coverage of retatrutide side effects and the retatrutide dosage chart, both built from the same trial records cited here.

Why do people keep asking about buying either peptide?

Headlines about a 24.2% weight loss number get attention, understandably ^[1]. And gray-market vendors know it, which is why retatrutide and AOD 9604 both show up on the same kind of research-chemical websites, often marketed side by side with vague research-use disclaimers. But wanting a drug and being able to lawfully obtain it are different questions. For a full breakdown of why retatrutide specifically can't be bought or compounded right now, see our retatrutide peptide buy guide. And if you want the broader picture on what retatrutide is and what the trials actually tested, our retatrutide peptide overview covers that in full.

Frequently asked questions

Is AOD 9604 the same thing as retatrutide?

No. AOD 9604 is a synthetic fragment of human growth hormone (amino acids 176-191) with a proposed fat-burning mechanism. Retatrutide is a triple agonist hitting the GIP, GLP-1, and glucagon receptors ^[7]. They're structurally and mechanistically unrelated, and only retatrutide has strong phase 2 human trial data behind it ^[1].

Does AOD 9604 actually work for fat loss?

The evidence is thin and old. Early trials didn't generate the kind of large, peer-reviewed, placebo-controlled results that would support real efficacy claims, and development stalled years ago. Compare that to retatrutide's published NEJM trial showing 24.2% mean weight loss at 48 weeks at the 12 mg dose ^[1]; AOD 9604 has nothing comparable.

Is retatrutide FDA-approved?

No. A Drugs@FDA search for the generic name retatrutide returns no approved product ^[1]. It remains an investigational drug studied in registered trials like NCT04881760, NCT05929066, and NCT05882045 ^[2][10][11], with no approved indication for weight loss, diabetes, or anything else.

Can a compounding pharmacy legally make AOD 9604 or retatrutide?

No, for both. Section 503A requires a substance to satisfy a monograph, be a component of an approved drug, or appear on the 503A Bulks List ^[3]. Neither peptide meets any of those three conditions, and neither appears on the six-substance Bulks List ^[4] or has ever been nominated for it ^[15].

Why do vendor websites say these are 'not for human consumption'?

That disclaimer is meant to dodge drug regulation, but FDA doesn't accept it at face value. Under 21 CFR 201.128, intended use is determined by labeling and marketing claims, not disclaimers ^[16]. FDA's 2026 warning letter to Gram Peptides found retatrutide marketed with human-use intent despite a research-use label ^[17].

What dose of retatrutide was used in the phase 2 trial?

The NEJM-published phase 2 trial tested weekly subcutaneous injections across several dose arms, with the 12 mg dose producing a mean 24.2% weight loss at 48 weeks versus 2.1% for placebo ^[1]. This was a supervised trial dose, not a recommendation; no clinician can currently prescribe retatrutide outside a registered trial.

Is it legal to import AOD 9604 or retatrutide for personal use?

Generally no. FDA's personal importation policy allows narrow exceptions for serious conditions with no approved US treatment, used under physician supervision in limited amounts ^[18]. Routine gray-market ordering for weight loss doesn't fit that exception, and both substances remain unapproved new drugs under 21 U.S.C. 355 ^[8].

What FDA-approved drugs work like retatrutide?

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are approved GLP-1 and GIP/GLP-1 drugs with published safety data ^[8]. Orforglipron, an oral GLP-1 agonist, was approved as Foundayo (NDA 220934) in strengths from 0.8 mg to 17.2 mg ^[8], giving an approved oral alternative.

Has AOD 9604 ever been considered for FDA's compounding Bulks List?

No public record shows AOD 9604 has been nominated for the 503A Bulks List. FDA's July 2026 Pharmacy Compounding Advisory Committee meeting reviewed seven different peptides (BPC-157, KPV, TB-500, MOTS-c, emideltide, semax, epitalon) ^[5]; AOD 9604 wasn't among them, and neither was retatrutide.

Does a favorable advisory committee review mean a peptide becomes legal to compound?

No. Advisory committee votes are non-binding recommendations. Actually adding a substance to the 503A Bulks List requires full notice-and-comment rulemaking ^[6], which is a separate, slower process with no guaranteed outcome. Neither AOD 9604 nor retatrutide has even reached the committee-review stage.

Which has better safety data, AOD 9604 or retatrutide?

Retatrutide has more human trial data, including monitored dosing in phase 2 and later-phase registered trials ^[1][10][11], so more is documented about its effects. AOD 9604's smaller evidence base means less is known either way. More trial data doesn't make either compound safe to self-administer outside supervised research.

What should someone do instead of trying to source either peptide?

Talk to a clinician about FDA-approved options: semaglutide, tirzepatide, or orforglipron, all with published safety monitoring ^[8]. NIDDK's federal weight management guidance is a neutral starting reference ^[19]. Neither AOD 9604 nor retatrutide can be lawfully prescribed or purchased in the US outside a registered clinical trial right now.

Sources

1. Jastreboff AM et al., New England Journal of Medicine, 2023: Retatrutide produced 24.2% mean weight loss at 12 mg vs 2.1% placebo at 48 weeks; retatrutide is a triple GIP/GLP-1/glucagon receptor agonist; retatrutide has no FDA approval
2. ClinicalTrials.gov NCT04881760: Phase 2 retatrutide obesity trial registration listing dose arms, LY3437943 code, and weekly subcutaneous injection route
3. 21 U.S.C. 353a(b)(1)(A)(i), Cornell Law: 503A compounding cascade requires monograph compliance, approved-drug component status, or Bulks List inclusion
4. 21 CFR 216.23, eCFR: Final 503A Bulks List contains exactly six substances, none a peptide, and retatrutide is not on it
5. Federal Register, Docket FDA-2025-N-6895: July 2026 Pharmacy Compounding Advisory Committee meeting reviewed seven peptides; retatrutide and AOD 9604 not among them
6. 21 U.S.C. 355, Cornell Law: New drugs cannot be introduced into interstate commerce without an approved application
7. ClinicalTrials.gov NCT05929066: Later-phase registered retatrutide trial listing enrollment criteria, comparators, and endpoints
8. ClinicalTrials.gov NCT05882045: Second later-phase retatrutide trial registration providing an independent record of dosing and design
9. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA's public 503A bulk substances list does not include retatrutide
10. 21 CFR 216.24, eCFR: Separate 503B bulks list also excludes retatrutide
11. FDA, Bulk Drug Substances Nominated for Use in Compounding (PDF): Retatrutide does not appear among nominated substances in Category 1, 2, or 3
12. 21 CFR 201.128, eCFR: Intended use is established by labeling claims, advertising, or seller statements, not disclaimers
13. FDA, Personal Importation: FDA's personal importation policy narrowly covers serious conditions without approved treatment, under physician supervision
14. NIDDK, Weight Management: Federal guidance on evidence-based weight management as a neutral reference point